Carmell (NASDAQ:CTCX – Get Free Report) and Modular Medical (NASDAQ:MODD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.
Valuation and Earnings
This table compares Carmell and Modular Medical”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Carmell | N/A | N/A | -$15.44 million | N/A | N/A |
Modular Medical | N/A | N/A | -$17.47 million | ($0.63) | -2.70 |
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Carmell | 0 | 0 | 0 | 0 | 0.00 |
Modular Medical | 0 | 0 | 1 | 0 | 3.00 |
Modular Medical has a consensus price target of $5.00, suggesting a potential upside of 194.12%. Given Modular Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Modular Medical is more favorable than Carmell.
Insider & Institutional Ownership
24.2% of Carmell shares are owned by institutional investors. Comparatively, 27.5% of Modular Medical shares are owned by institutional investors. 29.0% of Carmell shares are owned by company insiders. Comparatively, 32.3% of Modular Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Carmell and Modular Medical’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Carmell | N/A | -217.50% | -50.22% |
Modular Medical | N/A | -246.01% | -191.95% |
Risk & Volatility
Carmell has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Modular Medical has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
Summary
Modular Medical beats Carmell on 6 of the 9 factors compared between the two stocks.
About Carmell
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
About Modular Medical
Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.
Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.